What ADVA Biotechnologies does

ADVA Biotechnologies is an Israel-based private biotechnology company founded in 2016 that develops the ADVA X3, an automated, closed, single-use cell therapy manufacturing platform powered by its proprietary CAMP (Continuous Adaptive Multi-Parameter) technology. The system continuously monitors and regulates 14 critical parameters — including glucose, lactate, glutamine, glutamate, pH, dissolved oxygen, and gas flow rates — and uses AI/ML to adapt culture conditions in real time, predict metabolic alterations, and forecast cell counts. The proprietary shear-free Cone growth chamber supports expansion from 20 million to 20 billion cells (1000-fold) in a single run, with claimed 10X higher yields per chamber versus conventional methods and the ability to transition a CAR-T process from manual to fully automated cGMP in as little as three months. Supporting products include the CX900s single-use consumable kit and the ADVA Select upstream magnetic isolation module, extending coverage across cell selection, expansion, washing, and final formulation.

The company serves three primary customer segments: cell therapy developers and biotech companies (autologous and allogeneic CAR-T, TCR, TIL, NK therapies), contract development and manufacturing organizations (CDMOs) such as Cellipont Bioservices, and hospitals and academic medical centers pursuing decentralized point-of-care manufacturing. Revenue is generated through capital equipment sales of the ADVA X3 platform combined with recurring consumable revenue from CX900s single-use kits, supplemented by professional services, technical support, and channel revenue through CDMO partners. ADVA's regulatory footprint — ISO 13485:2016, CE marking, Class 1 Medical Device registration, FDA 21 CFR Part 11 / EU Annex 11 software compliance — enables the platform for cGMP manufacturing environments. The company is led by founder CEO Dr. Ohad Karnieli, with a board that includes Dr. Barbara Paldus (former Finesse Solutions founder, sold to ThermoFisher) and Prof. Gerhard Ehninger (founder/CEO of Cellex). No institutional funding rounds or revenue figures are disclosed in available materials.

Name

ADVA Biotechnologies

Legal name

Adva Biotechnology Ltd.

Website

https://advabio.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

ADVA Biotechnologies is an Israel-based private company developing the ADVA X3, an automated, single-use cell therapy manufacturing platform powered by proprietary CAMP technology and AI-driven real-time monitoring, serving cell therapy developers, CDMOs, and academic medical centers.

Ownership category

akta.pro rank

Product category

Cell Therapy Manufacturing Equipment

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

akta.pro secondary industry

Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)

Keywords

• Cell therapy manufacturing
• Automated bioreactor systems
• Single-use bioprocessing
• CAR-T manufacturing platform
• CGMP cell processing

Headquarters

HQ city

Haifa

HQ country

Israel

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. ADVA X3 Platform Hardware Sales: Sale of the ADVA X3 automated cell manufacturing device (80x80x80 cm3, 100Kg) to cell therapy developers, CDMOs, and academic medical centers. The platform is sold as capital equipment with associated single-use kits for each run.
2. CX900s Single-Use Disposable Kits: Recurring revenue from sale of CX900s single-use closed disposable kits used in each manufacturing run on the ADVA X3 platform. Each kit supports a complete cell therapy manufacturing run from seed to final formulation. Also includes specialized kits: CX-900TL (for TIL), CX-250E (for exosomes), CX-250V (for viruses).
3. ADVA Select Module & Kits: Sale of the ADVA Select magnetic T-cell isolation device and its associated single-use kits. This upstream module integrates with the ADVA X3 platform for enhanced cell selection workflows.
4. CDMO/Partner Channel Revenue: Revenue generated through CDMO partners like Cellipont Bioservices who integrate the ADVA X3 into their manufacturing service offerings, expanding market reach without direct end-customer sales.
5. Professional Services & Technical Support: Technical support, protocol customization, training, and potentially field services associated with the ADVA X3 platform deployment and optimization.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

ADVA Biotechnologies develops and sells the ADVA X3, an automated, single-use, closed cell therapy manufacturing platform powered by proprietary CAMP (Continuous Adaptive Multi-Parameter) technology. The platform continuously monitors and regulates 14 critical process parameters in real time using AI and machine learning, supporting end-to-end autologous and allogeneic cell therapy manufacturing (CAR-T, TCR, TIL, NK cells) as well as exosomes and viral vectors.配套 consumables include the CX900s single-use disposable kit and the ADVA Select magnetic cell isolation module.

Product overview

ADVA Biotechnology offers a unified platform architecture centered on the ADVA X3 cell manufacturing platform, a cGMP-compliant automated system for adoptive cell therapies. The platform is powered by proprietary CAMP (Continuous Adaptive Multi-Parameter) technology with AI and machine learning capabilities. Supporting products include the CX900s Single Use Kit (consumable) containing conditioning and growth chambers, and the ADVA Select Module (add-on) for upstream cell selection and magnetic isolation. The system supports CAR-T, TCR, TIL, NK, exosomes, and virus manufacturing applications.

Differentiator

Problem solved

Functional benefit

Brands

• ADVA X3: The flagship automated cell therapy manufacturing platform powered by CAMP technology for autologous cell therapy manufacturing including CAR-T, TCR, TIL, NK cells, exosomes, and viruses.
• CX900s Single Use Kit
• ADVA Select
• CAMP Technology

Products and services

• ADVA X3 Platform Innovative, robust, and flexible cGMP cell manufacturing platform powered by proprietary CAMP technology. It is a single-use, end-to-end system that integrates automated cell processing with AI-driven analytics for adoptive cell therapy manufacturing, including CAR-T, TCR, TIL, NK cells, exosomes, and viruses.
• CX900s Single Use Kit Flexible, user-friendly, compact, automated, and closed disposable kit optimized for production and downstream processing of CAR-T, TCR, TILs, NK cells, exosomes, and viruses. Contains a conditioning chamber and proprietary Cone growth chamber for continuous process manufacturing from seed to final formulation.
• ADVA Select Module Device for cell selection and incubation in the upstream process, designed for T-cell isolation from whole blood or PBMCs using magnetic separation technology. Integrates with the ADVA X3 bioreactor via USB and supports positive or negative isolation with programmable settings.

Quantifiable outcome

• 10X higher cell yields per chamber (up to 20 billion cells) compared to conventional culture methods
• +6 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature12 records

Partnerships

Five partnerships are on record, tiered core and flagship.

• Cubic BiocoreStrategic or Co-development Partner · 3 December 2025Adva Biotechnology and Cubic Bio announced a strategic collaboration in December 2025 to bring next-generation NK (Natural Killer) cell therapies to patients faster, at lower cost, and with enhanced quality and efficacy. Cubic Bio has developed a groundbreaking NK cell therapy leveraging innate cytotoxic abilities for scalable, off-the-shelf immunotherapies. Cubic Bio leverages Adva's ADVA X3 smart, flexible automated manufacturing platform with real-time metabolic sensing, AI-driven optimization, and a fully closed controlled system.
• Autolomous Ltd.coreStrategic or Co-development Partner · 6 October 2025Adva Biotechnology and Autolomous Ltd. (UK-based digital orchestration company) launched the Digital PIONEER Program in October 2025, combining Adva's automated manufacturing technologies with Autolomous' cloud-based orchestration software to deliver a fully integrated, digital, and scalable manufacturing solution for decentralized autologous cell therapy production. The program supports decentralized and scale-out deployment enabling personalized therapies to be produced closer to patients with higher throughput and greater consistency. GenCART Inc. joined as the first clinical partner.
• Autolomous Ltd.coreStrategic or Co-development Partner · 25 August 2025Announcement of strategic collaboration between Adva Biotechnology (Israel) and Autolomous (UK) to co-lead the Digital Pioneer Program, integrating Adva's automated closed-system manufacturing platform with Autolomous' digital orchestration and manufacturing management technologies. The goal is to establish right-first-time production processes with data traceability and regulatory compliance, aiming to shorten time-to-patient for advanced therapies.
• GenCART Inc.flagshipStrategic or Co-development Partner · 20 January 2025GenCART Inc. is the first clinical partner in the Digital PIONEER Program (joint Adva-Autolomous initiative). GenCART brings its therapeutic expertise in autologous T-cell therapies for oncology and immune disorders to validate the integrated platform through real-world application. The company contributes protocols, biological material, and performance data across lab-scale and pilot production phases to demonstrate clinical and operational benefits of the integrated automated/digital manufacturing model.
• Cellipont BioservicesflagshipChannel Partner/ Reseller/ Distributor · 7 May 2024Cellipont Bioservices, a premier cell therapy CDMO based in The Woodlands, Texas, partnered with Adva Biotechnology in May 2024 as the first CDMO in North America to offer the ADVA X3 platform. This partnership marked the launch of the ADVA X3 in North America. Cellipont provides CAR-T, NK, TCR, TIL, and exosome manufacturing services using the ADVA X3, enabling therapy developers to quickly go from manual processing to fully automated and GMP. At Advanced Therapies Week 2025 (January), both companies presented a showcase study demonstrating successful transition of a CAR-T process from complex manual workflow to automated solution with enhanced process control and consistency.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Ori Biotech: UK-based cell and gene therapy manufacturing platform company building automated, closed-system bioreactors and processing platforms for autologous and allogeneic cell therapies. Directly comparable as a dedicated cell therapy manufacturing automation vendor competing for the same therapy-developer and CDMO accounts as ADVA X3.
• Cellares: South San Francisco-based cell therapy manufacturing automation company offering the Cell Shuttle, an integrated and automated cell therapy manufacturing platform. Closely comparable to ADVA's end-to-end automated, closed-system approach for autologous cell therapy production at clinical and commercial scale.

Broad incumbents

• Miltenyi Biotec: German life sciences incumbent with the Prodigy platform for automated cell processing and a broad cell therapy reagent/consumables portfolio. Competes head-to-head with ADVA X3 in CAR-T and other cell therapy manufacturing workflows while offering a much wider installed base and instrument/reagent bundle.
• Cytiva: Danaher-owned bioprocessing incumbent (formerly GE Healthcare Life Sciences) offering the Xuri cell expansion system and a full bioprocess equipment and consumables portfolio used in cell and gene therapy manufacturing. Significant incumbent competitor to ADVA in bioreactor-based cell therapy manufacturing.
• Lonza: Swiss CDMO and bioprocess supplier offering the Cocoon automated cell therapy manufacturing platform and large-scale cell therapy manufacturing services. Competes both as a platform vendor to therapy developers and as a CDMO service using competing technology.
• Thermo Fisher Scientific: Global life sciences tools incumbent with the CTS Rotea and CTS G.Rex cell therapy processing systems (and former Finesse Solutions bioreactor assets). Competes with ADVA X3 as a comprehensive cell therapy manufacturing platform option from a large, well-capitalized supplier.

Emerging players

• ScaleReady: Joint venture (Bio-Techne, Wilson Wolf, and CellGenix) focused on simplifying and scaling cell and gene therapy manufacturing with the G.Rex and related platform offerings. Comparable to ADVA as a focused cell therapy manufacturing platform business, though with different go-to-market and reagent bundling model.

Others

• PBS Biotech: Manufacturer of single-use bioreactors used in cell therapy and regenerative medicine production. Comparable as a supplier of single-use, closed-system bioreactor hardware that competes for the same upstream manufacturing tool budget as the ADVA X3.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@advabiotechnology
• LinkedInlinkedin.com/company/adva-biotechnology

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ADVA Biotechnologies